Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Immuneering Corporation before investing.

In this article, we go over a few key elements for understanding Immuneering Corporation’s stock price such as:

• Immuneering Corporation’s current stock price and volume
• Why Immuneering Corporation’s stock price changed recently
• Upgrades and downgrades for IMRX from analysts
• IMRX’s stock price momentum as measured by its relative strength

About Immuneering Corporation (IMRX)

Before we jump into Immuneering Corporation’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Want to learn more about Immuneering Corporation’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Immuneering Corporation.

Immuneering Corporation’s Stock Price as of Market Close

As of November 28, 2025, 1:00 PM, CST, Immuneering Corporation’s stock price was $7.660.

Immuneering Corporation is up 2% from its previous closing price of $7.510.

During the last market session, Immuneering Corporation’s stock traded between $7.370 and $7.760. Currently, there are approximately 39.67 million shares outstanding for Immuneering Corporation.

Immuneering Corporation’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Immuneering Corporation Stock Price History

Immuneering Corporation’s (IMRX) price is currently up 11.5% so far this month.

During the month of November, Immuneering Corporation’s stock price has reached a high of $7.760 and a low of $5.980.

Over the last year, Immuneering Corporation has hit prices as high as $10.080 and as low as $1.100. Year to date, Immuneering Corporation’s stock is up 248.18%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Immuneering Corporation Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were 0 analysts who downgraded Immuneering Corporation’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Immuneering Corporation’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Immuneering Corporation’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Immuneering Corporation (IMRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Immuneering Corporation

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Immuneering Corporation has a weighted four-quarter relative price strength of 46.97%, which translates to a Momentum Score of 97 and is considered to be Very Strong.

Want to learn more about how Immuneering Corporation is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Immuneering Corporation Stock Price: Bottom Line

As of November 28, 2025, Immuneering Corporation’s stock price is $7.660, which is up 2% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Immuneering Corporation stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.